Deepbridge Capital's Andrew Aldridge, Partner & Chief of Marketing has recently been featured in IFA Magazine with his letter to our new Prime Minister, Liz Truss.

Andrew Aldridge, Partner & Chief of Marketing wrote:

"Dear Liz,

Deepbridge, through the Deepbridge Life Sciences EIS fund, has invested £300k into Ferryx, a Bristol-based biology technology start-up , in order to accelerate development of its innovative solution to common gut problems. 

Investee company within the Deepbridge Technology Growth EIS portfolio, Sky Medical Technology Ltd has recently announced that it's company Firstkind Ltd has joined the Legs Matter coalition as a gold corporate partner.

Elasmogen, which is part of the Deepbridge Life Sciences EIS fund, recently entered into a global license agreement with Intract Pharma Limited that gives Elasmogen exclusive access to Soteria® and Phloral® Technologies for oral colonic delivery of therapeutic proteins, der

Deepbridge Capital's Andrew Aldridge, Partner & Chief of Marketing has recently spoken with Professional Paraplanner to discuss how the Enterprise Investment Scheme (EIS) is not just a tax planning instrument for the ultra wealthy, but should be considered by any paraplanner carrying out estate planning for clients.

One of the potential inaccuracies regarding EIS and other tax efficient investments such as VCT's and Business Relief propositions

Deepbridge is delighted to commit £1m to a £2.25m funding round by existing investee company Liverpool ChiroChem.  We are pleased to be joined by funding partners from Praetura Ventures and NPIF - Maven Equity Finance, which is managed by Maven and part of the Northern Powerhouse Investment Fund, as part of the funding round.